Paul B. Westberg
Geen lopende functies
Profiel
Paul B.
Westberg worked as a Manager-Financial Planning & Analysis at Genentech, Inc. from 1996 to 1999.
He then worked as a Manager-Financial Planning & Analysis at MedImmune Vaccines, Inc. and as a Principal at Collabra Pharma, Inc. in 2000.
From 2002 to 2006, he served as Vice President-Business Development at Novacea, Inc. and as Principal at Deltagen, Inc. in 2002.
He was Vice President-Business Development at Bayhill Therapeutics, Inc. from 2006 to 2010.
Later, he worked as Chief Business Officer & Senior Vice President at Versartis, Inc. and as Senior Vice President-Business Development at Diartis Pharmaceuticals, Inc. He was Chief Business Officer at Aravive, Inc. from 2017 to 2018.
Mr. Westberg completed his undergraduate degree from the University of California San Diego and earned an MBA from the Haas School of Business.
Eerdere bekende functies van Paul B. Westberg
| Bedrijven | Functie | Einde |
|---|---|---|
| ARAVIVE, INC. | Corporate Officer/Principal | 12-10-2018 |
Bayhill Therapeutics, Inc.
 Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | Corporate Officer/Principal | - |
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Corporate Officer/Principal | 01-01-2006 |
| DELTAGEN INC. | Corporate Officer/Principal | 01-01-2002 |
| Collabra Pharma, Inc. | Corporate Officer/Principal | 01-01-2001 |
Opleiding van Paul B. Westberg
| University of California San Diego | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| DELTAGEN INC. | Commercial Services |
| ARAVIVE, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
MedImmune Vaccines, Inc.
 MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | Health Technology |
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | Health Technology |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
| Collabra Pharma, Inc. | |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
Diartis Pharmaceuticals, Inc.
 Diartis Pharmaceuticals, Inc. BiotechnologyHealth Technology Diartis Pharmaceuticals, Inc. developed therapeutic proteins for the treatment of metabolic disorders. The company was founded by Jeffrey L. Clearland in December 2010 and headquartered in Redwood City, CA. | Health Technology |
